Remove tag specialty-drugs
article thumbnail

Drug Pricing Reform: Never Out of the Headlines

Intouch Solutions

American politicians have been aware of, and looking for solutions to, drug pricing and affordability issues for literally decades. In their letter, “ Drug Pricing Reform in 2021 – Going Big or Going Bipartisan? When it comes to share of income, the burden of healthcare costs is the largest for Americans who have the lowest incomes.

Drugs 52
article thumbnail

Perfusion MRI and Other Perfusion Imaging Techniques for Clinical Trials

XTalks

However, the role of MRI in new drug clinical trials can involve diagnosis of lesions and determination of their severity, early identification of therapeutic responders to drug treatment and treatment monitoring and follow-up. An Example of an Anti-Angiogenic Therapy in Oncology. An Example of an Anti-Vascular Therapy in Oncology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche takes on pricey rivals as FDA approves SMA drug

pharmaphorum

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). While this is not cheap by anybody’s reckoning, Roche hopes that the less intimidating price tag, plus the patient-friendly oral administration method will give it a competitive edge.

article thumbnail

Ep. 005 – Dave Chase Podcast Transcript

Pharma Marketing Network

I mean probably the only real exception is in specialty pharma in terms of, underlying cost actually having gone up. Even there, that’s impacted by some distortions around pbms and how hospitals radically markup those drugs, but that’s probably the one exception. Don (PMN): The specialty pharmacy.

HR 40